This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Cerdelga

Sanofi

Drug Names(s): eliglustat, GENZ-112638

Description: GENZ 112638 is a ceramide analog given as an oral capsule. It is designed to inhibit the enzyme glucosylceramide synthase, which results in reduced production of glucocerebroside, a substance that builds up in patients with Gaucher disease. The pathway is also involved in Tay-Sachs, Sandhoff, and Fabry diseases.

Deal Structure: Genzyme originally licensed eliglustat from the University of Michigan.

Genzyme and Sanofi
In October 2010, Sanofi-aventis announced it has commenced a tender offer for all outstanding shares of common stock of Genzyme for $69 per share, net to the seller in cash, without interest and less any required withholding taxes. In April 2011, Sanofi-aventis announced that it successfully completed its exchange offer for all outstanding shares of common stock of Genzyme Corporation.

PDL and University of Michigan
In November 2014, acquired a portion of the University of Michigan's worldwide royalty interest in Cerdelga for $65.6 million. Under the terms of the royalty agreement, PDL will receive 75 percent of all royalty payments due under U-M's license agreement with Genzyme until expiration of the licensed patents, excluding any patent term extension. The royalty rate used to calculate the royalties to be paid by Genzyme to U-M was not disclosed by the...See full deal structure in Biomedtracker

Partners: PDL BioPharma, Inc. University of Michigan


Cerdelga News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug